Anthropic Expands Claude Into 6 Drug Partnerships, Targeting Human Trials by Late 2028
Updated
Updated · Anthropic · Oct 27
Anthropic Expands Claude Into 6 Drug Partnerships, Targeting Human Trials by Late 2028
3 articles · Updated · Anthropic · Oct 27
Summary
Six partnerships and Anthropic’s own drug programs now form the company’s push to embed Claude across drug discovery, manufacturing, regulatory filings and clinical-trial planning, with management saying it will scale the effort substantially.
Early case studies showed large efficiency gains: Enveda cut document review time 89% on 1,061 pages, while Claude drafted one regulatory document in four hours instead of roughly three months.
Lab-facing projects also produced stronger candidates. BigHat tested about 1,010 variants in 10 weeks and improved one lead’s binding by more than 10x, while Divergence used Claude to generate roughly 35,000 antibody designs in about a month.
Generate reported one Claude-assisted CAR-T design about 70% shorter than standard and roughly 10 times more productive in receptor output, and Bristol Myers Squibb is using Claude to assess early-stage trial plans ahead of a broader 2027 expansion.
Anthropic said most work remains preclinical, but its acquired muscular-dystrophy program could be ready to enter human trials as soon as late 2028, underscoring its aim to turn AI from a design tool into a full drug-development operating system.